Once-daily glecaprevir/pibrentasvir for 12 weeks is a well-tolerated and efficacious, ribavirin-free treatment option for patients with chronic hepatitis C virus (HCV) GT1-6 infection who had received a liver or kidney transplant, a recent study found. The phase 3, open-label trial was conducted in patients who were ≥3 months post-transplant. Patients without cirrhosis who were HCV treatment-naïve (GT1-6) or treatment experienced received glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks. The primary end point compared the percentage of patients receiving glecaprevir/pibrentasvir with sustained virologic response for 12 weeks (SVR12) to a historic SVR12 rate based on the standard of care. Researchers found:

• 80 liver and 20 kidney transplant patients were included.
• Most patients had no or minimal fibrosis and were infected with HCV GT1 or GT3.
• The overall SVR12 was 98%, exceeding the prespecified historic standard of care SVR12 threshold of 94%.
• Adverse events were mostly mild in severity.